

HR 3297

Counterfeit Drug Enforcement Act

Congress: 108 (2003–2005, Ended)

Chamber: House

Policy Area: Health

Introduced: Oct 15, 2003

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Oct 27, 2003)

Official Text: <https://www.congress.gov/bill/108th-congress/house-bill/3297>

Sponsor

Name: Rep. Israel, Steve [D-NY-2]

Party: Democratic • State: NY • Chamber: House

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Lowey, Nita M. [D-NY-18]	D · NY		Sep 8, 2004

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Oct 27, 2003

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Counterfeit Drug Enforcement Act - Amends the Federal Food, Drug, and Cosmetic Act to direct the Secretary of Health and Human Services, upon a finding of reasonable probability that a drug intended for human use would cause serious health consequences or death, to issue an order requiring the appropriate person (including the manufacturers, importers, distributors, or retailers of the drug) to: (1) cease distribution of the drug; (2) notify health professionals of the order and instruct such professionals to cease administering or prescribing the drug; and (3) amend the order to include a recall if necessary.

Provides a criminal fine and/or imprisonment for a person who knowingly caused a prescription drug to be adulterated or misbranded and sells or trades the drug, or who purchased or traded for the drug knowing or having reason to know that the drug was knowingly adulterated or misbranded.

Provides additional funding for Food and Drug Administration (FDA) inspections and investigations.

Modifies provisions pertaining to criminal penalties for committing certain prohibited acts involving food, drugs, devices, or cosmetics to: (1) make a violation punishable by a fine in accordance with Federal criminal law, imprisonment for not more than one year, or both; (2) make a second violation, or a violation committed with intent to defraud or mislead, punishable by a fine in accordance with Federal criminal law, imprisonment for not more than three years, or both; and (3) make a violation of provisions pertaining to prescription drug marketing punishable by a fine in accordance with Federal criminal law, imprisonment for not more than ten years, or both.

Actions Timeline

- **Oct 27, 2003:** Referred to the Subcommittee on Health.
- **Oct 15, 2003:** Introduced in House
- **Oct 15, 2003:** Introduced in House
- **Oct 15, 2003:** Referred to the House Committee on Energy and Commerce.